Global Integration Team Maps Out Strategies For Planet-wide Alliance Between Pfizer And Wyeth; Cuts Likely In The West, Matched By Expansion In China
This article was originally published in PharmAsia News
Executive Summary
BEIJING - As a global integration team crafts the contours of the pharmaceutical world's first megamerger of 2009, it is also mapping out strategies on how to create the strongest alliance possible between Pfizer and Wyeth while cutting $4 billion in costs and personnel by 2012
You may also be interested in...
Merck, Schering-Plough Aim To Be Among Top-Five Players In Emerging Markets
SHANGHAI - Merck expects to bring more than $2 billion in annual revenue from emerging markets and to meet its goal of reaching the top-five market share in targeted emerging markets following its merger with Schering-Plough
Merck, Schering-Plough Aim To Be Among Top-Five Players In Emerging Markets
SHANGHAI - Merck expects to bring more than $2 billion in annual revenue from emerging markets and to meet its goal of reaching the top-five market share in targeted emerging markets following its merger with Schering-Plough
Pfizer Increasing Size of China R&D Center, Expanding Virtual Research Network Through Alliances With Chinese Scientists, WuXi PharmaTech
BEIJING - Pfizer is set to ramp up its research and development center in Shanghai and to integrate more Chinese scientists into its worldwide virtual R&D network, including a new research deal with Wuxi PharmaTech, according to senior Pfizer executives in Shanghai and Hong Kong